Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
Clinical trial NCT02881320 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02881320
- Sponsor
- Gilead Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-21
- Primary completion
- 2025-03-24
- Enrollment
- 177
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.